Glicocortycosteroids (GS) are the most common therapy of multiple sclerosis relapses, however mechanism of beneficial effect is not fully known. The aim of our study was to evaluate the changes of immunological profile (percentage of lymphocytes B, T and monocytes, and produced by this cells IL-6 and IL-8) during intravenous administration of Solu-Medrol. Using two-colour flow cytometry we have studied peripheral blood of 10 patients during exacerbation. We have observed statistically significant improvement of distbility measured with EDSS. Statistically significant increase in lymphocyte B percentage and decrease in suppressor T cells was also noted. Results of our study indicate that GS therapy affects not only clinical state but also parameters of peripheral blood immune profile.